Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Finished Goods (2016 - 2026)

Ocular Therapeutix has reported Finished Goods over the past 13 years, most recently at $2.2 million for Q1 2026.

  • For Q1 2026, Finished Goods rose 72.91% year-over-year to $2.2 million; the TTM value through Mar 2026 reached $2.2 million, up 72.91%, while the annual FY2025 figure was $1.6 million, 22.74% up from the prior year.
  • Finished Goods for Q1 2026 was $2.2 million at Ocular Therapeutix, up from $1.6 million in the prior quarter.
  • Over five years, Finished Goods peaked at $2.2 million in Q1 2026 and troughed at $343000.0 in Q3 2022.
  • A 5-year average of $1.1 million and a median of $1.2 million in 2023 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: surged 198.05% in 2022 and later decreased 20.45% in 2024.
  • Year by year, Finished Goods stood at $766000.0 in 2022, then grew by 29.37% to $991000.0 in 2023, then surged by 34.91% to $1.3 million in 2024, then grew by 22.74% to $1.6 million in 2025, then soared by 34.55% to $2.2 million in 2026.
  • Business Quant data shows Finished Goods for OCUL at $2.2 million in Q1 2026, $1.6 million in Q4 2025, and $1.9 million in Q3 2025.